Key result
Higher invasive sPAP is linked to ~3% greater 2-year death or HFH risk after T-TEER.
Why the study?
Does baseline pulmonary hypertension predict adverse outcomes in patients undergoing transcatheter tricuspid valve edge-to-edge repair for relevant tricuspid regurgitation?
Cohort (n=1,230)
Yes
Does baseline pulmonary hypertension predict adverse outcomes in patients undergoing transcatheter tricuspid valve edge-to-edge repair for relevant tricuspid regurgitation?
Pulmonary hypertension, specifically sPAP >46 mm Hg, is an independent predictor of death or heart failure hospitalization in patients undergoing T-TEER for tricuspid regurgitation, though procedural success and symptom improvement occur irrespective of PH.
Answers are grounded in this paper and cite their sources.
Baseline sPAP elevation identifies higher 2-year risk after T-TEER; leaves open whether PH modification improves outcomes.
BACKGROUND: Data regarding the association of pulmonary hypertension (PH) and outcomes in patients undergoing transcatheter tricuspid valve edge-to-edge repair (T-TEER) are scarce. OBJECTIVES: The aims of this study were: 1) to investigate the impact of PH on outcomes after T-TEER; and 2) to shed further light on the role of precapillary- and postcapillary PH in patients undergoing T-TEER for relevant tricuspid regurgitation (TR). METHODS: The study included patients from EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation; NCT06307262) who underwent T-TEER for relevant TR from 2016 until 2023 with available invasive evaluation of systolic pulmonary artery pressure (sPAP) using right heart catheterization. Study endpoints were procedural TR reduction, improvement in NYHA function class, and a combined endpoint of death or heart failure hospitalization (HFH) at 2 years. RESULTS: Among a total of 1,230 patients (mean age 78.6 ± 7.0 years, 51.4% women), increasing sPAP was independently associated with increasing rates of 2-year death or HFH (HR: 1.027; 95% CI: 1.003-1.052; P = 0.030; median survival follow-up 343 days [Q1-Q3: 114-645 days]). No significant survival differences were observed for patients with pre- vs postcapillary PH. Sensitivity analysis revealed an sPAP value of 46 mm Hg as the optimized threshold for the prediction of death or HFH. Being observed in 526 patients (42.8%), elevated sPAP (>46 mm Hg) was associated with more severe heart failure symptoms at baseline and follow-up. Importantly, NYHA functional class significantly improved and TR severity was significantly reduced irrespective of PH. CONCLUSIONS: PH is an important outcome predictor in patients undergoing T-TEER for relevant TR. In contrast to previous studies, no significant differences were observed for patients with precapillary and postcapillary PH in terms of survival free from HFH.
No takes yet. Share an insight, caveat, or question.
Stolz et al. (2024) conducted a cohort in Tricuspid regurgitation (n=1,230). Increasing systolic pulmonary artery pressure (sPAP) vs. Lower systolic pulmonary artery pressure was evaluated on Combined endpoint of all-cause death or heart failure hospitalization (HFH) at 2 years (HR 1.027, 95% CI 1.003-1.052, p=0.030). Increasing invasive systolic pulmonary artery pressure was independently associated with an increased risk of 2-year death or heart failure hospitalization (HR 1.027) after transcatheter tricuspid valve edge-to-edge repair.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: